Journal Article

Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases

Enrique Morales, Victor Gutiérrez Millet, Jorge Rojas-Rivera, Ana Huerta, Eduardo Gutiérrez, Elena Gutiérrez-Solís, Jesús Egido and Manuel Praga

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 28, issue 2, pages 405-412
Published in print February 2013 | ISSN: 0931-0509
Published online December 2012 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfs429
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases

Show Summary Details

Preview

Background

Several studies have demonstrated a short-term antiproteinuric effect of mineralocorticoid receptor blockers (MRB) on proteinuric kidney diseases, but no information is available about the long-term persistence (>1 year) of such reduction in proteinuria and the long-term effects of MRB on renal function.

Methods

We prospectively studied the effects of adding spironolactone (25 mg/day) to 87 patients who maintained proteinuria higher than 1 g/day in spite of renin–angiotensin system blockade. The mean follow-up was 25 ± 15 (1–84) months.

Results

Estimated glomerular filtration rate (eGFR) showed an acute fall in the first month of treatment (5.1 ± 9.4 mL/min/1.73 m2), but it remained stable thereafter (+0.04 ± 0.7 mL/min/1.73 m2/month), with a significant difference with respect to the eGFR slope during the 12-month pre-treatment period. The initial eGFR fall predicted a more stable course of renal function, the higher the eGFR initial fall, the better the long-term evolution of eGFR. Proteinuria showed an important and sustained reduction since the first month of treatment. At the end of follow-up, it had decreased by 61% (43–77%) with respect to baseline values. The antiproteinuric and renoprotective influence of spironolactone was also observed in diabetic patients and in patients with renal function impairment, although tolerance was poorer among the latter.

Conclusions

Spironolactone induces an initial acute fall in eGFR that predicts a later favourable influence on the course of renal function and a remarkable and sustained reduction in proteinuria.

Keywords: aldosterone; mineralocorticoid receptor blocker; proteinuria; renoprotective; spironolactone

Journal Article.  4533 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.